AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Explore expert insights on the fundamentals of cancer, including how it develops, key risk factors, prevention strategies, and treatment options. This section also highlights cancer awareness months and related observance days and weeks. Commentaries from our network of oncology professionals shed light on critical issues that require greater attention across the cancer care and research continuum.
Dr. L. Christine Fang on Modern De-Escalation in Breast Cancer Radiation Therapy
By The Cancer News Team
Dr. L. Christine Fang reviews modern de-escalation strategies in breast cancer radiation therapy, including hypofractionation, partial breast irradiation, and radiation omission for selected patients.
Dr. L. Christine Fang on Modern De-Escalation in Breast Cancer Radiation Therapy
By The Cancer News Team
Dr. L. Christine Fang reviews modern de-escalation strategies in breast cancer radiation therapy, including hypofractionation, partial breast irradiation, and radiation omission for selected patients.
Dr. L. Christine Fang on Modern De-Escalation in Breast Cancer Radiation Therapy
By The Cancer News Team
Dr. L. Christine Fang reviews modern de-escalation strategies in breast cancer radiation therapy, including hypofractionation, partial breast irradiation, and radiation omission for selected patients.
Dr. Brie Chun on Who Really Needs More Adjuvant Therapy in Early-Stage Breast Cancer?
By The Cancer News Team
Dr. Brie Chun reviews long-term SOFT and TEXT trial data to clarify which premenopausal patients with early-stage hormone receptor–positive breast cancer benefit most from ovarian function suppression.
Dr. Brie Chun on Who Really Needs More Adjuvant Therapy in Early-Stage Breast Cancer?
By The Cancer News Team
Dr. Brie Chun reviews long-term SOFT and TEXT trial data to clarify which premenopausal patients with early-stage hormone receptor–positive breast cancer benefit most from ovarian function suppression.
Dr. Brie Chun on Who Really Needs More Adjuvant Therapy in Early-Stage Breast Cancer?
By The Cancer News Team
Dr. Brie Chun reviews long-term SOFT and TEXT trial data to clarify which premenopausal patients with early-stage hormone receptor–positive breast cancer benefit most from ovarian function suppression.
Dr. Emily N. Palmquist on De-escalation of Axillary Surgery in Early-Stage Breast Cancer
By The Cancer News Team
Dr. Emily N. Palmquist reviews evidence from SOUND, INSEMA, and BOOG trials on safely omitting sentinel lymph node biopsy in select patients with early-stage breast cancer.
Dr. Emily N. Palmquist on De-escalation of Axillary Surgery in Early-Stage Breast Cancer
By The Cancer News Team
Dr. Emily N. Palmquist reviews evidence from SOUND, INSEMA, and BOOG trials on safely omitting sentinel lymph node biopsy in select patients with early-stage breast cancer.
Dr. Emily N. Palmquist on De-escalation of Axillary Surgery in Early-Stage Breast Cancer
By The Cancer News Team
Dr. Emily N. Palmquist reviews evidence from SOUND, INSEMA, and BOOG trials on safely omitting sentinel lymph node biopsy in select patients with early-stage breast cancer.
Dr. Chaitra S. Ujjani on B-Cell Lymphoma: Bispecific Antibodies and CAR T-Cell Therapy Updates from ASH
By The Cancer News Team
Expert highlights from Dr. Chaitra S. Ujjani on bispecific antibodies and CAR T-cell therapy in B-cell lymphomas, featuring key efficacy, safety, and practice-changing updates from the 2025 ASH meeting.
Dr. Chaitra S. Ujjani on B-Cell Lymphoma: Bispecific Antibodies and CAR T-Cell Therapy Updates from ASH
By The Cancer News Team
Expert highlights from Dr. Chaitra S. Ujjani on bispecific antibodies and CAR T-cell therapy in B-cell lymphomas, featuring key efficacy, safety, and practice-changing updates from the 2025 ASH meeting.
Dr. Chaitra S. Ujjani on B-Cell Lymphoma: Bispecific Antibodies and CAR T-Cell Therapy Updates from ASH
By The Cancer News Team
Expert highlights from Dr. Chaitra S. Ujjani on bispecific antibodies and CAR T-cell therapy in B-cell lymphomas, featuring key efficacy, safety, and practice-changing updates from the 2025 ASH meeting.
Dr. Ghulam Rehman Mohyuddin on Relapsed/Recurrent Multiple Myeloma: CAR T-Cell Therapy and Bispecific Antibody Strategies
By The Cancer News Team
Dr. Ghulam Rehman Mohyuddin reviews modern treatment strategies for relapsed multiple myeloma, comparing CAR T-cell therapy and bispecific antibodies, with practical guidance on sequencing and patient selection.
Dr. Ghulam Rehman Mohyuddin on Relapsed/Recurrent Multiple Myeloma: CAR T-Cell Therapy and Bispecific Antibody Strategies
By The Cancer News Team
Dr. Ghulam Rehman Mohyuddin reviews modern treatment strategies for relapsed multiple myeloma, comparing CAR T-cell therapy and bispecific antibodies, with practical guidance on sequencing and patient selection.
Dr. Ghulam Rehman Mohyuddin on Relapsed/Recurrent Multiple Myeloma: CAR T-Cell Therapy and Bispecific Antibody Strategies
By The Cancer News Team
Dr. Ghulam Rehman Mohyuddin reviews modern treatment strategies for relapsed multiple myeloma, comparing CAR T-cell therapy and bispecific antibodies, with practical guidance on sequencing and patient selection.
Dr. Akshat Jain on Cancer-Associated Thrombosis: Latest Advances from ASH 2025
By The Cancer News Team
Dr. Akshat Jain reviews key advances in cancer-associated thrombosis from ASH 2025, covering epidemiology, pathophysiology, anticoagulation strategies, and evidence-based guidance for prevention and treatment.
Dr. Akshat Jain on Cancer-Associated Thrombosis: Latest Advances from ASH 2025
By The Cancer News Team
Dr. Akshat Jain reviews key advances in cancer-associated thrombosis from ASH 2025, covering epidemiology, pathophysiology, anticoagulation strategies, and evidence-based guidance for prevention and treatment.
Dr. Akshat Jain on Cancer-Associated Thrombosis: Latest Advances from ASH 2025
By The Cancer News Team
Dr. Akshat Jain reviews key advances in cancer-associated thrombosis from ASH 2025, covering epidemiology, pathophysiology, anticoagulation strategies, and evidence-based guidance for prevention and treatment.
Are We Finally Making Progress Against Triple-Negative Breast Cancer? Dr. Lynn Symonds Weighs In
By The Cancer News Team
Dr. Lynn Symonds reviews recent advances in triple-negative breast cancer, including adjuvant carboplatin, PARP inhibitor combinations, and emerging ADCs—highlighting progress while underscoring persistent unmet needs.
Are We Finally Making Progress Against Triple-Negative Breast Cancer? Dr. Lynn Symonds Weighs In
By The Cancer News Team
Dr. Lynn Symonds reviews recent advances in triple-negative breast cancer, including adjuvant carboplatin, PARP inhibitor combinations, and emerging ADCs—highlighting progress while underscoring persistent unmet needs.
Are We Finally Making Progress Against Triple-Negative Breast Cancer? Dr. Lynn Symonds Weighs In
By The Cancer News Team
Dr. Lynn Symonds reviews recent advances in triple-negative breast cancer, including adjuvant carboplatin, PARP inhibitor combinations, and emerging ADCs—highlighting progress while underscoring persistent unmet needs.
Dr. Michael Snyder on Advances in Genomic Medicine: Multi-Omics Approaches to Cancer Research and AI Applications in Precision Health
By The Cancer News Team
Dr. Michael Snyder of Stanford Medicine discusses how multi-omics research and artificial intelligence are reshaping cancer biology, early detection, and precision health, using familial adenomatous polyposis as a model.
Dr. Michael Snyder on Advances in Genomic Medicine: Multi-Omics Approaches to Cancer Research and AI Applications in Precision Health
By The Cancer News Team
Dr. Michael Snyder of Stanford Medicine discusses how multi-omics research and artificial intelligence are reshaping cancer biology, early detection, and precision health, using familial adenomatous polyposis as a model.
Dr. Michael Snyder on Advances in Genomic Medicine: Multi-Omics Approaches to Cancer Research and AI Applications in Precision Health
By The Cancer News Team
Dr. Michael Snyder of Stanford Medicine discusses how multi-omics research and artificial intelligence are reshaping cancer biology, early detection, and precision health, using familial adenomatous polyposis as a model.
Stanford Medicine Clinicians Highlight How Radiologists, Surgeons, and Pathologists Can Advance Precision Oncology Treatment
By The Cancer News Team
Stanford Medicine experts discuss how radiology, surgery, and pathology inform precision oncology, highlighting imaging phenotypes, treatment response assessment, and opportunities for surgical de-escalation in breast cancer care.
Stanford Medicine Clinicians Highlight How Radiologists, Surgeons, and Pathologists Can Advance Precision Oncology Treatment
By The Cancer News Team
Stanford Medicine experts discuss how radiology, surgery, and pathology inform precision oncology, highlighting imaging phenotypes, treatment response assessment, and opportunities for surgical de-escalation in breast cancer care.
Stanford Medicine Clinicians Highlight How Radiologists, Surgeons, and Pathologists Can Advance Precision Oncology Treatment
By The Cancer News Team
Stanford Medicine experts discuss how radiology, surgery, and pathology inform precision oncology, highlighting imaging phenotypes, treatment response assessment, and opportunities for surgical de-escalation in breast cancer care.
Dr. Stephen B. Gruber on Germline Genetic Testing in Cancer Treatment Drag
By The Cancer News Team
Dr. Stephen B. Gruber discusses how germline genetic testing shapes cancer therapy selection, reveals gaps in current guidelines, and presents INSPIRE study data supporting universal access to comprehensive genetic testing.
Dr. Stephen B. Gruber on Germline Genetic Testing in Cancer Treatment Drag
By The Cancer News Team
Dr. Stephen B. Gruber discusses how germline genetic testing shapes cancer therapy selection, reveals gaps in current guidelines, and presents INSPIRE study data supporting universal access to comprehensive genetic testing.
Dr. Stephen B. Gruber on Germline Genetic Testing in Cancer Treatment Drag
By The Cancer News Team
Dr. Stephen B. Gruber discusses how germline genetic testing shapes cancer therapy selection, reveals gaps in current guidelines, and presents INSPIRE study data supporting universal access to comprehensive genetic testing.